NeXtGen Biologics

Growth Stage

Patented, FDA Cleared, Novel Wound-Care Technology. New Skin In The Game!

Analytics

Raised to Date: Raised: $120,375

Aggregate Commitments $

Platform

Republic

Start Date

09/02/2022

Close Date

02/28/2023

Min. Goal

$25,000

Max. Goal

$5,000,000

Min. Investment

$250

Security Type

SAFE

Funding Type

RegCF

Series

Series A

Valuation Cap

$40,000,000

Discount Rate

0%

Rolling Commitments $

Status

Active

Reporting Date

11/27/2022

Days Remaining

93

% of Min. Goal

482%

% of Max. Goal

2%

Likelihood of Max
unlikely
Avg. Daily Raise

$1,400

# of Investors

151

Momentum
cold.svg
Create a free account today to gain access to KingsCrowd analytics.
Location

Alachua, Florida

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Business Type

High Growth

NeXtGen Biologics, with a valuation of $40 million, is raising funds on Republic. The company has developed a patented and FDA-cleared wound-care technology involving the extracellular matrix (ECM). The technology captures the regenerative power of the axolotl and has potential applications in general surgery, wounds and burns, plastic surgery, cardiovascular diseases, ophthalmology, and gastrointestinal diseases. The first product of NeXtGen Biologics, NEOMATRIX, is the first ECM product derived from the axolotl and available to physicians and patients. Jonelle Toothman founded NeXtGen Biologics in April 2014. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5 million. The campaign proceeds will be used for the soft and full-scale launch of NEOMATRIX.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$-110,221

$51,772

 

 

Net Income

$-2,007,144

$-790,983

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$337,233

$516,897

Accounts Receivable

$0

$0

Total Assets

$1,547,848

$2,069,171

Short-Term Debt

$9,761,500

$9,110,917

Long-Term Debt

$0

$155,400

Total Liabilities

$9,761,500

$9,266,317

Financials as of: 09/02/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
NeXtGen Biologics on Republic 2022
$
Platform: Republic
Security Type: SAFE
Valuation: $40,000,000

Follow company

Follow NeXtGen Biologics on Republic 2022
View on Republic
Bullish / Bearish
You're Bullish on NeXtGen Biologics on Republic 2022

Thank you for your vote on NeXtGen Biologics on Republic 2022

Bullish / Bearish
You're Bearish on NeXtGen Biologics on Republic 2022

Thank you for your vote on NeXtGen Biologics on Republic 2022